Sumitomo Chemical

Sumitomo Chemical is a leading Japanese chemical and life sciences conglomerate with significant operations in pharmaceutical chemicals, APIs, oligonucleotides, regenerative medicine/cell therapies, and advanced medical solutions. It serves as a major global CDMO for top pharma companies. Its group includes Sumitomo Pharma with an extensive clinical pipeline spanning psychiatry/neurology, oncology, women’s health, rare diseases and more. The company has robust manufacturing capabilities for both small molecules and advanced modalities like oligonucleotides and cell therapies. Recent clinical highlights include late-stage development of ulotaront for schizophrenia/depression/anxiety disorders; approval of MYFEMBREE® for endometriosis; active radiopharmaceutical programs; ongoing expansion into regenerative medicine manufacturing.